These Analysts Slash Their Forecasts On Insulet After Q2 Results - Insulet (NASDAQ:PODD)

Benzinga
Open on Benzinga

Insulet Corp. (NASDAQ: PODD ) on Wednesday posted upbeat second-quarter results but lowered its full-year revenue guidance.

Adjusted earnings rose to $1.66 per share from $1.17 a year earlier, beating the analyst consensus estimate of $1.45. Revenue increased 23.5% year over year to $801.7 million, topping the Street estimate of $787.2 million.

"We delivered another quarter of broad-based growth, robust margin expansion, and positive free cash flow," CEO Ashley McEvoy said.

For the third quarter, Insulet expects revenue of approximately $829.9 million to $844.0 million, below the analyst consensus estimate of $845.5 million.

The company also lowered its full-year 2026 revenue outlook to a range of approximately $3.25 billion to $3.30 billion from its prior forecast of $3.28 billion to $3.33 billion. The revised guidance also came in below the Wall Street estimate of $3.32 billion.

Insulet shares fell 1.4% to $131.37 in pre-market trading.

These analysts made changes to their price targets on Insulet following earnings announcement.

Considering buying PODD stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here .


Posted In: Trading Ideas Pre-Market Outlook News Analyst Ratings Price Target Earnings PT Changes